Inclusion Criteria:  Age: ≥18 years old, no gender limit. Diagnosed as advanced non-small cell lung cancer. At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm. Doctors evaluate the benefits of receiving Anlotinib treatment. The patient voluntarily joins the project and signs the informed consent. If any of the above items is "No", the patient is not suitable for this study.  Exclusion Criteria:  Those who have been confirmed to be allergic to anlotinib and/or its excipients. Patients with anlotinib contraindications.